Quinoline Derivatives for the Treatment of Inflammatory Diseases
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2015/066458, filed Jul 17, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,435,370 | Quinoline Derivatives for the Treatment of Inflammatory Diseases In force · High confidence UsedRemaining | Abivax, Centre National de la Recherche Scientifique, Institut Curie and Universite de Montpellier | In force | High confidence | ||
| US 10,981,874 | Use of Quinoline Derivatives for the Treatment of Inflammatory Diseases In force · High confidence | Abivax | In force | High confidence | ||
| US 11,649,210 | Use of Quinoline Derivatives for the Treatment of Inflammatory Diseases In force · Low confidence | Abivax | In force | Low confidence | ||
| US 11,649,211 | Use of Quinoline Derivatives for the Treatment of Inflammatory Diseases In force · Low confidence | Abivax | In force | Low confidence | ||
| US 12,202,804 | In Vitro or Ex Vivo Methods for Screening a Quinoline Derivative In force · High confidence | Abivax | In force | High confidence | ||
| Application 18/973,608 | In Vitro or Ex Vivo Methods for Screening a Quinoline Derivative Pending Not granted | Abivax | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Universite de Montpellier.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.